 NEW YORK, July 14, 2021 GLOBE NEWSWIRE -- BeyondSpring the Company or BeyondSpring NASDAQ: BYSI, a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective immediately. Mr. Delaney brings his significant expertise in commercial oncology drug launches. BeyondSprings lead developmental asset, plinabulin, is currently under Priority Review by the U.S. Food and Drug Administration FDA for the prevention of chemotherapy-induced neutropenia CIN with a U.S. Prescription Drug User Fee Act PDUFA action date of November 30, 2021. Mr. Delaney is expected to play an important role in the commercial launch planning for plinabulin and implementation, pending successful regulatory review. 